Recent developments in the use of immunotherapy in non-small cell lung cancer

Mariacarmela Santarpia, Elisa Giovannetti, Christian Rolfo, Niki Karachaliou, Maria González-Cao, Giuseppe Altavilla, Rafael Rosell

Research output: Contribution to journalReview article

Abstract

Introduction: Targeted therapies have significantly improved the prognosis of subsets of patients with advanced non-small-cell lung cancer (NSCLC) harboring somatically activated oncogenes, such as mutant EGFR and rearranged ALK. However, the efficacy of these agents is limited by the development of acquired resistance which occurs after variable periods of time. Therefore, there is an urgent need for novel therapeutic strategies to achieve long lasting disease control, as well as new therapies for those patients without targetable driver mutations. A deeper understanding of interactions between the immune system and tumor cells has led to the development of a number of immunotherapeutic agents. Areas covered: We review current data on immunotherapy for lung cancer treatment, with a focus on checkpoint inhibitors and therapeutic vaccines. References for this review were identified through searches of PubMed, congress proceedings and reference lists from key original and review papers. Expert commentary: While most vaccines have been unsuccessful, inhibitors of specific immune checkpoints, including CTLA-4 and PD-1/PD-L1 pathway, have shown significant clinical activity and manageable toxicities and recently, two anti-PD-1 monoclonal antibodies have been approved by the FDA for treatment of patients with advanced NSCLC. Identification of reliable predictive biomarkers for patient selection and novel rational combinations are currently active areas of research to further improve the efficacy of immunotherapy.

Original languageEnglish
Pages (from-to)781-798
Number of pages18
JournalExpert Review of Respiratory Medicine
Volume10
Issue number7
DOIs
Publication statusPublished - Jul 2 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Therapeutics
Vaccines
Oncogenes
PubMed
Patient Selection
Immune System
Lung Neoplasms
Biomarkers
Monoclonal Antibodies
Mutation
Research
Neoplasms

Keywords

  • cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)
  • immune checkpoint inhibitors
  • Non-small-cell lung cancer
  • programmed cell death ligand-1 (PD-L1)
  • programmed cell death protein-1 (PD-1)

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health

Cite this

Santarpia, M., Giovannetti, E., Rolfo, C., Karachaliou, N., González-Cao, M., Altavilla, G., & Rosell, R. (2016). Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Review of Respiratory Medicine, 10(7), 781-798. https://doi.org/10.1080/17476348.2016.1182866

Recent developments in the use of immunotherapy in non-small cell lung cancer. / Santarpia, Mariacarmela; Giovannetti, Elisa; Rolfo, Christian; Karachaliou, Niki; González-Cao, Maria; Altavilla, Giuseppe; Rosell, Rafael.

In: Expert Review of Respiratory Medicine, Vol. 10, No. 7, 02.07.2016, p. 781-798.

Research output: Contribution to journalReview article

Santarpia, M, Giovannetti, E, Rolfo, C, Karachaliou, N, González-Cao, M, Altavilla, G & Rosell, R 2016, 'Recent developments in the use of immunotherapy in non-small cell lung cancer', Expert Review of Respiratory Medicine, vol. 10, no. 7, pp. 781-798. https://doi.org/10.1080/17476348.2016.1182866
Santarpia M, Giovannetti E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G et al. Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Review of Respiratory Medicine. 2016 Jul 2;10(7):781-798. https://doi.org/10.1080/17476348.2016.1182866
Santarpia, Mariacarmela ; Giovannetti, Elisa ; Rolfo, Christian ; Karachaliou, Niki ; González-Cao, Maria ; Altavilla, Giuseppe ; Rosell, Rafael. / Recent developments in the use of immunotherapy in non-small cell lung cancer. In: Expert Review of Respiratory Medicine. 2016 ; Vol. 10, No. 7. pp. 781-798.
@article{1b2ecea8861d40da971616830a1ee1b6,
title = "Recent developments in the use of immunotherapy in non-small cell lung cancer",
abstract = "Introduction: Targeted therapies have significantly improved the prognosis of subsets of patients with advanced non-small-cell lung cancer (NSCLC) harboring somatically activated oncogenes, such as mutant EGFR and rearranged ALK. However, the efficacy of these agents is limited by the development of acquired resistance which occurs after variable periods of time. Therefore, there is an urgent need for novel therapeutic strategies to achieve long lasting disease control, as well as new therapies for those patients without targetable driver mutations. A deeper understanding of interactions between the immune system and tumor cells has led to the development of a number of immunotherapeutic agents. Areas covered: We review current data on immunotherapy for lung cancer treatment, with a focus on checkpoint inhibitors and therapeutic vaccines. References for this review were identified through searches of PubMed, congress proceedings and reference lists from key original and review papers. Expert commentary: While most vaccines have been unsuccessful, inhibitors of specific immune checkpoints, including CTLA-4 and PD-1/PD-L1 pathway, have shown significant clinical activity and manageable toxicities and recently, two anti-PD-1 monoclonal antibodies have been approved by the FDA for treatment of patients with advanced NSCLC. Identification of reliable predictive biomarkers for patient selection and novel rational combinations are currently active areas of research to further improve the efficacy of immunotherapy.",
keywords = "cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), immune checkpoint inhibitors, Non-small-cell lung cancer, programmed cell death ligand-1 (PD-L1), programmed cell death protein-1 (PD-1)",
author = "Mariacarmela Santarpia and Elisa Giovannetti and Christian Rolfo and Niki Karachaliou and Maria Gonz{\'a}lez-Cao and Giuseppe Altavilla and Rafael Rosell",
year = "2016",
month = "7",
day = "2",
doi = "10.1080/17476348.2016.1182866",
language = "English",
volume = "10",
pages = "781--798",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Recent developments in the use of immunotherapy in non-small cell lung cancer

AU - Santarpia, Mariacarmela

AU - Giovannetti, Elisa

AU - Rolfo, Christian

AU - Karachaliou, Niki

AU - González-Cao, Maria

AU - Altavilla, Giuseppe

AU - Rosell, Rafael

PY - 2016/7/2

Y1 - 2016/7/2

N2 - Introduction: Targeted therapies have significantly improved the prognosis of subsets of patients with advanced non-small-cell lung cancer (NSCLC) harboring somatically activated oncogenes, such as mutant EGFR and rearranged ALK. However, the efficacy of these agents is limited by the development of acquired resistance which occurs after variable periods of time. Therefore, there is an urgent need for novel therapeutic strategies to achieve long lasting disease control, as well as new therapies for those patients without targetable driver mutations. A deeper understanding of interactions between the immune system and tumor cells has led to the development of a number of immunotherapeutic agents. Areas covered: We review current data on immunotherapy for lung cancer treatment, with a focus on checkpoint inhibitors and therapeutic vaccines. References for this review were identified through searches of PubMed, congress proceedings and reference lists from key original and review papers. Expert commentary: While most vaccines have been unsuccessful, inhibitors of specific immune checkpoints, including CTLA-4 and PD-1/PD-L1 pathway, have shown significant clinical activity and manageable toxicities and recently, two anti-PD-1 monoclonal antibodies have been approved by the FDA for treatment of patients with advanced NSCLC. Identification of reliable predictive biomarkers for patient selection and novel rational combinations are currently active areas of research to further improve the efficacy of immunotherapy.

AB - Introduction: Targeted therapies have significantly improved the prognosis of subsets of patients with advanced non-small-cell lung cancer (NSCLC) harboring somatically activated oncogenes, such as mutant EGFR and rearranged ALK. However, the efficacy of these agents is limited by the development of acquired resistance which occurs after variable periods of time. Therefore, there is an urgent need for novel therapeutic strategies to achieve long lasting disease control, as well as new therapies for those patients without targetable driver mutations. A deeper understanding of interactions between the immune system and tumor cells has led to the development of a number of immunotherapeutic agents. Areas covered: We review current data on immunotherapy for lung cancer treatment, with a focus on checkpoint inhibitors and therapeutic vaccines. References for this review were identified through searches of PubMed, congress proceedings and reference lists from key original and review papers. Expert commentary: While most vaccines have been unsuccessful, inhibitors of specific immune checkpoints, including CTLA-4 and PD-1/PD-L1 pathway, have shown significant clinical activity and manageable toxicities and recently, two anti-PD-1 monoclonal antibodies have been approved by the FDA for treatment of patients with advanced NSCLC. Identification of reliable predictive biomarkers for patient selection and novel rational combinations are currently active areas of research to further improve the efficacy of immunotherapy.

KW - cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)

KW - immune checkpoint inhibitors

KW - Non-small-cell lung cancer

KW - programmed cell death ligand-1 (PD-L1)

KW - programmed cell death protein-1 (PD-1)

UR - http://www.scopus.com/inward/record.url?scp=84975475669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975475669&partnerID=8YFLogxK

U2 - 10.1080/17476348.2016.1182866

DO - 10.1080/17476348.2016.1182866

M3 - Review article

AN - SCOPUS:84975475669

VL - 10

SP - 781

EP - 798

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 7

ER -